Current and Future Therapies for Immunogenic Cell Death and Related Molecules to Potentially Cure Primary Breast Cancer

SIMPLE SUMMARY: How a cure for primary breast cancer after (neo)adjuvant therapy can be achieved at the molecular level remains unclear. Immune activation by anticancer drugs may contribute to the eradication of residual tumor cells by postoperative (neo)adjuvant chemotherapy. In addition, chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ryungsa, Kin, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507525/
https://www.ncbi.nlm.nih.gov/pubmed/34638242
http://dx.doi.org/10.3390/cancers13194756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507525/
https://www.ncbi.nlm.nih.gov/pubmed/34638242
http://dx.doi.org/10.3390/cancers13194756

Ejemplares similares